[4th July, 2014] Gilead Sciences, Australia New Zealand, today announced that the Therapeutic Goods Administration has approved Sovaldi® (sofosbuvir), a new direct acting antiviral treatment, for the treatment of chronic hepatitis C infection in adults as a component of a combination antiviral treatment regimen.
“Currently, chronic hepatitis C has a high diagnosis rate but a low treatment rate,” said Professor Gregory Dore, Head of the Viral Hepatitis Clinical Research Program, Kirby Institute. “Sofosbuvir is a major advance for hepatitis C treatment, enabling shorter treatment duration and less side effects. Its efficacy, lack of resistance, and once daily dosing, should place Sofosbuvir at the forefront of the new era of improved treatments for people living with hepatitis C,” he added.